Treating IgG4-related disease with mild steroid starts
Part of Immune system & allergy clinical trials.
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you meet IgG4-related disease diagnosis rules (per ACR/EULAR 2019).
- Your disease is newly diagnosed or has come back (relapsed).
- You need to start or continue steroid (glucocorticoid) treatment.
- The steroid dose you started is less than 10 mg per day (or it is being continued from that low starting point).
- You do not have another autoimmune disease instead of IgG4-related disease.
- You are not currently pregnant or breastfeeding, and you do not have active infections like HIV, hepatitis B/C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial tests whether a medication called lenalidomide helps keep your IgG4-related disease in remission and prevents it from coming back. It is for people whose disease is well controlled on low-dose steroids.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.